Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2/ Phase 3 Study of NA-921 (Bionetide) for the Treatment of Girls and Women with Rett Syndrome
NCT06849973 is registered in ClinicalTrials.gov with Biomed Industries, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2/ Phase 3 Study of NA-921 (Bionetide) for the Treatment of Girls and Women with Rett Syndrome
- Lead sponsor
- Biomed Industries, Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- March 15, 2024
- Completion date
- January 28, 2025
- Enrollment
- 187 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.